Gastric Cancer Market Expected to Reach $10.7 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Gastric Cancer Market," The gastric cancer market size was valued at $2.1 billion in 2021, and is estimated to reach $10.7 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031.

A type of cancer that begins in the cells lining of the stomach is known as gastric cancer, also referred to as stomach cancer. Abdominal discomfort, bloating, nausea, vomiting, and weight loss are some of the signs and symptoms of gastric cancer. Gastric cancer treatment options include surgery, chemotherapy, radiation therapy, or a combination of these. The increasing incidence of gastric cancer is attributed to various factors, including dietary habits, lifestyle factors, and infection with Helicobacter pylori (H. pylori), a bacterium that can cause chronic gastritis and gastric ulcers.

Gastric cancer is the fifth most common malignancy in the world and one of the leading causes of cancer-related deaths. The increase in disease burden and the approval of pipeline candidates are expected to drive the market growth during the forecast period. Rapid approvals from regulatory authorities associated with gastric cancer are projected to result in enormous growth opportunities for the stomach cancer market. Ongoing R&D activities are important in the development of new drugs and therapies. These developments are anticipated to result in significant growth opportunities for the gastric cancer market growth.

Factors such as high treatment costs, a lack of effective early detection methods, and a lack of new treatment options are predicted to hamper the market revenue growth during the forecast period. For patients in developing countries, the high cost of treatment is a major barrier to access. Furthermore, many stomach cancer cases are not diagnosed until they are advanced due to a lack of effective early detection methods. All these factors are expected to restrain the gastric cancer market size expansion in the future.

Advancements in medical technology and research are providing new and innovative approaches to the diagnosis and treatment of gastric cancer. For example, targeted therapy and immunotherapy are emerging as promising treatment options for certain types of gastric cancer. By educating the public about the risk factors and symptoms of gastric cancer and investing in innovative treatments, patient outcomes can be improved and reduce the impact of this disease. This, in turn, can increase the demand for diagnostic and treatment options, including drugs, surgery, and radiation therapy. With the increase in healthcare awareness, there is a growing opportunity for the gastric cancer industry players in the future. 

The gastric cancer market share is segmented on the basis of disease type, treatment type, drug class outlook, route of administration, distribution channel, and region. By disease type, it is classified into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others. By treatment type, it is classified into immunotherapy, targeted therapy, chemotherapy, and radiation therapy and surgery. By disease type, it is classified into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others. By drug class outlook, it is classified into PD-1/PD-L1 inhibitors, HER2 antagonists, VEGFR2 antagonists, and others. By route of administration, it is classified into oral and injectable. By distribution channel, it is classified into hospital pharmacies, specialty & retail pharmacies, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in the gastric cancer market analysis report include Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company.

The report offers a comprehensive analysis of the global gastric cancer market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also highlights the present scenario and upcoming trends & developments that are contributing toward the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.

Impact of COVID-19 on the Global Gastric Cancer Industry

• The COVID-19 pandemic had a negative impact on gastric cancer care, particularly in terms of delays in screening, diagnosis, and treatment. It is important for healthcare systems to prioritize the management of patients with gastric cancer and develop strategies to address the impact of the pandemic on cancer care.
• Gastric cancer treatment procedures had been modified to minimize the risk of COVID-19 transmission, which led to delays or changes in treatment plans for some patients. Patients were also hesitant to receive treatment due to concerns about COVID-19 exposure in healthcare settings.
• The pandemic had a significant impact on clinical trials for gastric cancer. Many clinical trials were put on hold or delayed due to the pandemic, which slowed the development of new treatments and therapies for the disease.

Key Findings of the Study

• Based on disease type, the adenocarcinoma sub-segment emerged as the global leader in 2021 and is anticipated to be the fastest growing during the gastric cancer market forecast period
• Based on treatment type, the chemotherapy sub-segment emerged as the global leader in 2021 and the targeted therapy sub-segment is predicted to show the fastest growth in the upcoming years
• Based on drug class outlook, the PD-1/PD-L1 inhibitors sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
• Based on route of administration, the oral sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
• Based on distribution channel, the specialty & retail pharmacies sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
• Based on region, the Asia-Pacific market registered the highest gastric cancer market share in 2021 and is projected to maintain its position during the forecast period